MedTrace Logo

Scalp Cooling to Prevent Chemo-induced Hair Loss

NCT01986140 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 236

Last updated 2021-07-27

Study results available
· View outcomes & findings →

Summary

Determine that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.

Conditions

Interventions

DEVICE

PAXMAN Orbis Scalp Cooler

Treatment with Orbis scalp cooling cap

OTHER

Control No treatment

No treatment to prevent hair loss

Sponsors & Collaborators

  • Julie Nangia

    lead OTHER

Principal Investigators

  • Julie Nangia, M.D. · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-15
Primary Completion
2017-02-10
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01986140 on ClinicalTrials.gov